more

HealthEquity (HQY)

(Delayed Data from NSDQ)

$98.82 USD

+1.62 (1.67%)

Updated Nov 8, 2024 03:59 PM ET

After-Market: $98.64 -0.18 (-0.18%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5 2

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth D Momentum B VGM

Industry Rank:

Bottom 42% (145 out of 250)

Industry: Medical Services

View All Zacks #1 Ranked Stocks

Zacks News

Here's Why You Should Add DexCom (DXCM) to Your Portfolio

by Zacks Equity Research Published on January 22,2020

DexCom (DXCM) expects its strong product portfolio to consistently drive top line.

medical

Nevro (NVRO) Gains Ground on Solid Preliminary Q4 Results

by Zacks Equity Research Published on January 16,2020

Higher revenues and upbeat 2020 worldwide revenue outlook benefit Nevro's (NVRO) preliminary Q4 results.

medical

Allscripts Expands Partnership With PIH Health Through 2025

by Zacks Equity Research Published on January 16,2020

Encouraged by its solid EHR prospects, Allscripts (MDRX) expects a surge in its fourth-quarter 2019 bookings.

medical

Inogen (INGN) Announces Preliminary Q4 Results, Slashes View

by Zacks Equity Research Published on January 15,2020

Inogen (INGN) expects direct-to-consumer sales to be its fastest-growing channel in 2020.

medical

ABIOMED (ABMD) Announces Preliminary Q3 Results, Slashes View

by Zacks Equity Research Published on January 14,2020

ABIOMED's (ABMD) Q3 international revenues grew year over year; fiscal 2020 view slashed.

medical

Teladoc to Buy InTouch Health, Expand Reach in Virtual Care

by Zacks Equity Research Published on January 13,2020

Teladoc (TDOC) to acquire InTouch Health and provide virtual health solutions ranging from critical to everyday care.

medical

Here's Why You Should Add Cerner (CERN) to Your Portfolio

by Zacks Equity Research Published on January 10,2020

Cerner (CERN) expects revenues between $1.41 billion and $1.46 billion in the fourth quarter.

medical

Here's Why You Should Hold on to AngioDynamics Stock Now

by Zacks Equity Research Published on January 09,2020

AngioDynamics (ANGO) retains fiscal 2020 view; VA revenues soft in fiscal Q2.

medical

Walgreens Boots (WBA) Q1 Earnings Lag Estimates, Margins Fall

by Zacks Equity Research Published on January 08,2020

Sluggishness in Walgreens Boots' (WBA) Retail Pharmacy International segment and margin contractions put pressure on the bottom line during Q1.

AngioDynamics (ANGO) Q2 Earnings Top, Revenues Lag Estimates

by Zacks Equity Research Published on January 08,2020

AngioDynamics (ANGO) gains from core Oncology business in the fiscal second quarter, reiterates guidance.

Walgreens Boots (WBA) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research Published on January 06,2020

Higher comparable pharmacy sales and expanded comparable prescription volume are likely to have aided growth in Walgreens Boots' (WBA) Retail Pharmacy USA during the first quarter of fiscal 2020.